Drug

Pabinafusp alfa clinical trials

Also written JR-141.

studies test it: 7
open now: 1
in phase 3: 4
first study started: 2017

How each study uses pabinafusp alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the pabinafusp alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States: Not in FDA's approval records
European Union: Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

JR-141: 7

Studies by the year they started

7 studies that test it; most in 2018 (2)

Studies that test pabinafusp alfa, by start year
Year	Studies
2017	1
2018	2
2019	2
2022	1
2023	1

By phase

A phase 1/2 study counts in both.

Phase 1: 1
Phase 2: 5
Phase 3: 4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Mucopolysaccharidosis II: 7

Who runs them

Industry 7 · Other 0

JCR Pharmaceuticals Co., Ltd. (7)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2, 1 in phase 3

Studies that test pabinafusp alfa, phase 3 first.

Oct 2027A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)Phase 3 · JCR Pharmaceuticals Co., Ltd.
Dec 2026An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis IIPhase 2 · JCR Pharmaceuticals Co., Ltd.

Studies

Open first, then newest update. How each study uses pabinafusp alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 7

Codes

What other systems call pabinafusp alfa · ClinicalTrials.gg INT018044

UNII (FDA) TRF8S0U6ONPABINAFUSP ALFAConfirmed FDA, Wikidata
Wikidata Q107327238pabinafusp alfaConfirmed FDA, Wikidata
NCI Thesaurus C170281Pabinafusp AlfaOne source FDA
DrugBank DB15633One source Wikidata

System	Code	Name there	Checked by
UNII (FDA)	TRF8S0U6ON	PABINAFUSP ALFA	Confirmed FDA, Wikidata
Wikidata	Q107327238	pabinafusp alfa	Confirmed FDA, Wikidata
NCI Thesaurus	C170281	Pabinafusp Alfa	One source FDA
DrugBank	DB15633	—	One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.